INMUNE BIO ($INMB) posted quarterly earnings results on Thursday, March 27th. The company reported earnings of -$0.40 per share, beating estimates of -$0.55 by $0.15. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $INMB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INMUNE BIO Insider Trading Activity
INMUNE BIO insiders have traded $INMB stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $INMB stock by insiders over the last 6 months:
- DAVID J MOSS (Chief Financial Officer) purchased 10,000 shares for an estimated $52,868
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
INMUNE BIO Hedge Fund Activity
We have seen 46 institutional investors add shares of INMUNE BIO stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC. added 141,904 shares (+62.4%) to their portfolio in Q3 2024, for an estimated $764,862
- UBS GROUP AG added 93,092 shares (+215.7%) to their portfolio in Q4 2024, for an estimated $434,739
- MILLENNIUM MANAGEMENT LLC added 88,823 shares (+43.9%) to their portfolio in Q4 2024, for an estimated $414,803
- PEKIN HARDY STRAUSS, INC. added 83,350 shares (+inf%) to their portfolio in Q4 2024, for an estimated $389,244
- RENAISSANCE TECHNOLOGIES LLC added 78,600 shares (+73.3%) to their portfolio in Q4 2024, for an estimated $367,062
- CORTON CAPITAL INC. removed 76,143 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $355,587
- MORGAN STANLEY added 62,982 shares (+68.4%) to their portfolio in Q4 2024, for an estimated $294,125
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
